Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview 7 Therapeutics Development 8 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development 8 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area 9 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication 10 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance 12 Early Stage Products 12 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies 13 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Universities/Institutes 16 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development 24 Amgen Inc. 24 Axxam SpA 25 Bionomics Limited 26 conoGenetix biosciences GmbH 27 Johnson & Johnson 28 Kineta, Inc. 29 Sevion Therapeutics, Inc. 30 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles 31 BNC-164 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 cgtx-A - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 cgtx-F - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 cgtx-G - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 dalazatide - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 KPI-150 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 KPI-190 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 OSK-1 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 SVN-001 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects 48 Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Featured News & Press Releases 50 Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 50 May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 51 May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference 51 Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases 51 Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases 52 Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 52 Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting 53 Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation 54 Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus 54 Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting 55 Jun 05, 2015: Sevion Therapeutics to Present at International Antibody Meeting 55 May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases 56 May 04, 2015: Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015 57 Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease 58 Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Amgen Inc., H1 2016 24 Pipeline by Axxam SpA, H1 2016 25 Pipeline by Bionomics Limited, H1 2016 26 Pipeline by conoGenetix biosciences GmbH, H1 2016 27 Pipeline by Johnson & Johnson, H1 2016 28 Pipeline by Kineta, Inc., H1 2016 29 Pipeline by Sevion Therapeutics, Inc., H1 2016 30 Dormant Projects, H1 2016 48 Dormant Projects (Contd..1), H1 2016 49 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

Amgen Inc. Axxam SpA Bionomics Limited conoGenetix biosciences GmbH Johnson & Johnson Kineta, Inc. Sevion Therapeutics, Inc.